Serum urate and incidence of kidney disease among veterans with gout

Journal of Rheumatology

Volumn 40, Issue 7, 2013, Pages 1166-1172

  Krishnan, Eswar ^a   Akhras, Kasem S ^b   Sharma, Hari ^c   Marynchenko, Maryna ^c   Wu, Eric ^c   Tawk, Rima H ^a   Liu, Jinan ^d   Shi, Lizheng ^d  

^a STANFORD UNIVERSITY   (United States)

^b Takeda Pharmaceuticals International Inc   (United States)

^c ANALYSIS GROUP   (United States)

^d TULANE UNIVERSITY   (United States)

Author keywords

Gout; Hyperuricemia; Kidney Disease; Serum Urate; Uric Acid

Indexed keywords

URATE;

ADULT; ARTICLE; BODY MASS; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; FOLLOW UP; GOUT; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES; URIC ACID BLOOD LEVEL; VETERAN;

GOUT; HYPERURICEMIA; KIDNEY DISEASE; SERUM URATE; URIC ACID;

AGED; BODY MASS INDEX; COMORBIDITY; GOUT; HUMANS; HYPERURICEMIA; INCIDENCE; KIDNEY DISEASES; MALE; MIDDLE AGED; PREVALENCE; RISK; URIC ACID; VETERANS;

EID: 84879973746     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121061     Document Type: Article

References (40)

1. Crittenden DB, Pillinger MH. The year in gout-2010-2011. Bull NYU Hosp Jt Dis 2011;69:257-63.
2. Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS ONE 2012;7:e50046.
3. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: Prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960-6.
4. Terkeltaub R, Zelman D, Scavulli J, Perez-Ruiz F, Liote F. Gout Study Group: Update on hyperuricemia and gout. Joint Bone Spine 2009;76:444-6.
5. Krishnan E. Gout and coronary artery disease: Epidemiologic clues. Curr Rheumatol Rep 2008;10:249-55.
6. Kang DH, Nakagawa T. Uric acid and chronic renal disease: Possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 2005;25:43-9.
7. Fuldeore MJ, Riedel AA, Zarotsky V, Pandya BJ, Dabbous O, Krishnan E. Chronic kidney disease in gout in a managed care setting. BMC Nephrol 2011;12:36.
8. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011;63:3136-41.
9. Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleve Clin J Med 2006; 73:1059-64.
10. Ginsberg MH, Kozin F, O'Malley M, McCarty DJ. Release of platelet constituents by monosodium urate crystals. J Clin Invest 1977;60:999-1007.
11. Sánchez-Lozada LG, Tapia E, Santamaría J, Avila-Casado C, Soto V, Nepomuceno T, et al. Mild hyperuricaemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005;67:237-47.
12. Feig DI. Uric acid: A novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 2009;18:526-30.
13. Avram Z, Krishnan E. Hyperuricaemia-Where nephrology meets rheumatology. Rheumatology 2008;47:960-4.
14. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008;19:2407-13.
15. Chen YC, Su CT, Wang ST, Lee HD, Lin SY. A preliminary investigation of the association between serum uric acid and impaired renal function. Chang Gung Med J 2009;32:66-71.
16. Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009;169:342-50.
17. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008;19:1204-11.
18. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001;24:691-7.
19. Chen N, Wang W, Huang Y, Shen P, Pei D, Yu H, et al. Community-based study on CKD subjects and the associated risk factors. Nephrol Dial Transplant 2009;24:2117-23.
20. Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 2010;56:264-72.
21. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007;50:239-47.
22. Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol 2008;43:347-52.
23. See LC, Kuo CF, Chuang FH, Li HY, Chen YM, Chen HW, et al. Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate. J Rheumatol 2009;36:1691-8.
24. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009;53:796-803.
25. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000;151:488-96.
26. Meliker JR, Wahl RL, Cameron LL, Nriagu JO. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: A standardised mortality ratio analysis. Environ Health 2007;6:4.
27. Van Staa, TP, Travis S, Leufkens HG, Logan RF. 5-aminosalicylic acids and the risk of renal disease: A large British epidemiologic study. Gastroenterology 2004;126:1733-9.
28. Sonoda H, Takase H, Dohi Y, Kimura G. Uric acid levels predict future development of chronic kidney disease. Am J Nephrol 2011;33:352-7.
29. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004;44:642-50.
30. Hsu CY, Ordonez JD, Chertow GM, Fan D, McCulloch CE, Go AS. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 2008;74:101-7.
31. Reynolds K, Gu D, Muntner P, Chen J, Wu X, Yau CL, et al. Body mass index and risk of ESRD in China. Am J Kidney Dis 2007;50:754-64.
32. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997;51:1908-19.
33. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988;318:1657-66.
34. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84:1074-8.
35. US Renal Data System. USRDS 2010 annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010:2.
36. Borges RL, Hirota AH, Quinto BM, Ribeiro AB, Zanella MT, Batista MC. Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy. J Clin Hypertens 2009;11:253-9.
37. Park JT, Kim DK, Chang TI, Kim HW, Chang JH, Park SY, et al. Uric acid is associated with the rate of residual renal function decline in peritoneal dialysis patients. Nephrol Dial Transplant 2009;24:3520-5.
38. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: Long-term treatment effects of febuxostat. J Clin Rheumatol 2011;17:7-13.
39. Singh JA. Accuracy of Veterans Affairs database for gout-related health care utilization [abstract]. Arthritis Rheum 2012:63 Suppl:S771.
40. Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: A validation study. Am J Kidney Dis 2005;46:225-32.